DoseAble is a line of 3D printed accessibility devices for injectable medications for patients with poor dexterity, created by a group of 9 Doctor of Pharmacy students. The syringe-style case acts as a stabilizing support system for the insulin pen by allowing for push back against the applied force of the patient’s thumb on the injector. This means that the device absorbs some of the force and, as a result, patients will not need to press as hard to deliver the dose. DoseAble enables patients to efficiently and independently administer their dose and allows for ease and steadier administration of injectable medications. The device is lightweight, portable and multi-use, and recyclable.

Key Features Include:

• Ergonomic grip for improved stability

• Allows easier access to the pressing surface by providing a stable reaction force against the thumb when pressing the injector, allowing for easier injection

• Product name and colour differentiation for basal versus bolus devices

• All variants are inscribed with Braille, both for the visually impaired and for added grip support

• Compatible with common insulin pen models including Basaglar, Tresiba, Trurapi, and Apidra with room to expand to other models and other injectables

• Stable when stored at 2-8˚C (can be left attached to an insulin pen when not in use)

Vision: To empower patients with dexterity limitations to independently and confidently administer medication through accessible assistive technology.

Mission: DoseAble aims to improve accessibility and safety in insulin administration by providing a device that stabilizes insulin pens and simplifies the injection process for patients with reduced hand function. 

Objectives:

• Improving accessibility of insulin administration for patients with dexterity impairments.

• Increasing patient confidence and independence in diabetes self-management

• Reducing medication administration errors associated with insulin injections.

• Supporting pharmacists and healthcare providers in optimizing patient outcomes.